5^th Annual Conference on Stroke and Neurological Disorders November 12-13, 2018 Amsterdam, Netherlands

Tayfun Uzbay has completed his PhD at the age of 32 years from Gulhane Medical School in Ankara and postdoctoral studies from University of North Texas, Department of Pharmacology and Neuroscience in USA and University of Cagliari, Department of Toxicology in Italy. He is the director of Neuropsychopharmacology Application and Research Center (NPARC) at Üsküdar University in Ä°stanbul. Professor Uzbay is a founder of Psychopharmacology Research Unit in Turkey. His research studies have focused on Behavioral Neuroscience. He has patents of some molecules for schizophrenia treatment. He has published more than 200 papers in reputed journals and citations more than 3500.

One of the most intriguing and fundamental properties of brain function is the ability to sustain long-term changes in patterns of neuronal activity. This concept, called neuroplasticity or brain plasticity, refers to the ability of adaptation and change-ability of brain within the time. Sometimes the reorganization or re-adaptation mediates vital and important physiological events such as learning and memory by LTP; but sometimes, especially under internal or external heavy stressful conditions, the statement is called as contra-adaptation and it is responsible for several neuropsychiatric diseases.

Neuroplasticity is a continuous process in reaction to neuronal activity and neuron injury, death, and genesis, which involves modulation of structural and functional processes of axons, dendrites and synapses. Elements of signal transduction cascade (SDC) between the neurons include in neurotransmitters, receptors, G proteins, second messengers, protein kinases, and transcription factors. If anyone of these elements has failure, pathological conditions (contra-adaptation) occur in brain. Each step of neurotransmission is influenced by changes in genes and DNA in SDC. In fact, neuroplasticity is a result of adaptive genomic changes in SDC and it is a product of gene plasticity or genoplasticity. However, the term genoplasticity does not frequently used in literature. Today, we do not have any radical solutions in treatment of important neuropsychiatric diseases such as autism, schizophrenia, addiction and Alzheimer yet. Some external and internal factors may change task definition of neurons by causing genomic changes and occurring mutant or terrorist neurons may cause severe brain disorders. We should also approach to neuropsychiatric diseases in aspect to genoplasticity.

Yavuz Selim SILAY is the chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube Ä°stanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel Ä°laç Archem Diagnostices Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara,Turkey.

Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how decisions at the US ,Europe, Turkey and emerging markets are taken at the federal and state level and how it will impact provider and patient access and coverage to their therapies. To gain these critical insights, Government Affairs & Medical affairs teams require speaking with those on the frontlines of healthcare delivery - physicians, allied healthcare professionals, payers, and patients. New generation government engagement and commercial diplomacy approach developed by ICG (Istanbul Consulting Group) will be provided with unique cases. Dr. Yavuz Selim SILAY a global leader and seasoned expert in Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how companies utilizing Government Affairs and Medical affairs teams should engage decision makers, payers,physicians and acquire these insights in a convenient, cost-effective, and compliant manner in this current changing global regulatory landscape.